Corporate Sponsored Funding
PIVOT Center works with companies to thoroughly understand their R&D goals and match them to research goals of the appropriate faculty members at the University of Utah. PIVOT’s Corporate Engagement team works across all schools and units to facilitate partnerships and offer expertise on identifying opportunities that include grant funding, sponsored research and creating strategic corporate partnerships. PIVOT also provides guidance to faculty for successful stewardship. Please contact Sadhna Kohli (Director of Corporate Engagement) for more information regarding these opportunities, or if you have any questions.
Pfizer: Patient and Caregiver Awareness of Drug Resistant Infections
Deadline: May 19, 2021
Projects that will be considered for Pfizer support will focus on patient and caregiver awareness on the importance of appropriate use of intravenous or home infusion anti-infectives (antibiotics or antifungals) as a part of chronic disease management, including oncology, diabetes, hematology, immunology, renal disorders, rheumatology, pulmonology, and patients with long-term hospital stays.
Chan Zuckerberg Initiative: Ancestry Networks for the Human Cell Atlas RFA
Deadline: May 21, 2021
This Request for Applications (RFA) is intended to bring together teams of experts to 1) ethically and appropriately generate data derived from tissues from people whose ancestral groups are historically understudied and thereby expand the ancestral diversity of single-cell data that is available via the HCA, and 2) utilize best practices and build up systems to enable long-term engagement of potential participants and donors from diverse communities to contribute to the current and future drafts of the HCA. This work will help provide insights into the contribution of genetic ancestry to disease now and in the future, resulting in an atlas that may be more generalizable and representative of the diversity found in the global human population.
Facebook: 2021 Networking request for proposals: Internet and web services
Deadline: May 24, 2021
Networking research has a wide range of topics. Each year, we focus on specific topics that can benefit the research community and Facebook, and topics may change from year to year. This year, we are soliciting proposals focusing on internet and web services. The example topics include the following:
- Internet transport protocols (e.g., QUIC, HTTP/3)
- Content delivery techniques (e.g., load balancing, telemetry)
- Distributed caching
- Edge computing services
Pfizer: Addressing Primary Immunodeficiencies within Minority/Underserved Populations
Deadline: May 25, 2021
Primary immunodeficiencies occur in all patient populations but the
diagnoses are infrequently made in minority populations in the US. These
disparities have been noted in several studies. Through this RFP, the intent is to support patient and provider educational programs on the awareness, diagnosis, and treatment of primary immunodeficiencies within minority/underserved populations.
Takeda: 2022 Innovators in Science Award in Gastroenterology
Deadline: Nomination deadline May 27, 2021
Established in 2016, the Innovators in Science Award is administered by the New York Academy of Sciences and sponsored by Takeda Pharmaceuticals. This global award recognizes a promising Early-Career Scientist's and an outstanding Senior Scientist's contributions to biomedical science and is intended to support their commitment to innovative research.
Two prizes of US$200,000 are awarded each Award cycle to winning scientists who have distinguished themselves for the creativity and impact of their research in a designated therapeutic area.
Pfizer: Pediatric Endocrinology Fellowship
Deadline: June 1st, 2021
The intent is to support institutions with fellowship programs for Pediatric Endocrinologists that have a strong focus on clinical practice, research, and education to further the understanding of short stature/growth failure
Pfizer: 2021 Growth Hormone Research
Deadline: June 1st, 2021
Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature. Projects submitted may include:
- Diagnostics, early treatment, new treatment paradigms
- Clinical outcomes, quality of life, and patient reported outcomes
- Medication adherence research
- Translational or clinical research
Pfizer: Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients
with Rare Disease
Deadline: June 1, 2021
Projects that will be considered for Pfizer support will focus on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.
Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
Deadline: June 1st, 2021
Projects that will be considered for Pfizer support will focus on:
- Morbidity and mortality in Growth Hormone Excess
- Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat Growth Hormone Excess
- Early diagnosis and treatment of Growth Hormone Excess
- Pathophysiology of Growth Hormone Excess
Pfizer: Addressing Social Health Needs in Chronic and Preventative Disease
Deadline: June 2, 2021
The intent of this RFP is to encourage proposals to join a Learning and Action Network (LAN) to support the journey of health care organizations seeking to integrate social care into health care delivery in pursuit of improved health, well-being, and equity for their populations. The LAN will focus on the social care integration work of 3-5 integrated delivery networks (IDNs) in the United States, also known as health systems - organizations that own and operate a network of one or more health care facilities. Each selected IDN will set 12-month goals specific to their contexts. Participants will test social care integration strategies with their patient populations and share their results both with one another and stakeholders in their own IDNs to enhance the rate of learning and improvement. This LAN will be convened by IHI and funded by Pfizer.
Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.
Deadline: June 9, 2021
Projects that will be considered for Pfizer support will focus on several or one
- Early identification, evaluation, diagnosis, prognosis & treatment
- Study of hereditary ATTR genotypes and phenotypes
- Non-Val30Met genotypes
- Val122Ile, Thr60Ala, Val30Met, and others
- Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
- Use of tafamidis in the clinical setting (i.e. real-world evidence)
Pfizer: Racial and Ethnic Disparities in the Menopause Experience
Deadline: June 10, 2021
Projects that will be considered for Pfizer support will focus on increasing awareness and understanding among health care providers about racial and ethnic differences in patients’ menopause experiences. Closing these knowledge gaps are important to help ensure that patients receive proper diagnosis, appropriate treatment and optimal care.
Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive
Deadline: June 15, 2021
Projects that will be considered for funding will focus on supporting the development of nurse navigator programs, including training, in order to improve the quality of care for ATTR-CM patients.
Pfizer: Management of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular
Risk in NASH
Deadline: June 15, 2021
Pfizer intent is to provide an independent grant(s) to an organization or organizations that will focus on the management of metabolic disorders’ risks that drive liver disease outcomes and increase cardiovascular risk in non-alcoholic steatohepatitis (NASH). Projects that will be considered for Pfizer support will focus on:
- Innovative treatment approaches to reduce the risk of, slow or prevent progression to severe liver outcomes such as advanced fibrosis, cirrhosis, hepatocellular carcinoma, or liver transplant
- Understanding the linkage of NAFLD/NASH and cardiovascular disease in patients with NASH
- Understanding the contribution of NAFLD/NASH to overall morbidity and mortality risks
Pfizer: Transthyretin Cardiac Amyloidosis Fellowship
Deadline: June 15th, 2021
The intent is to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grants will be available for both established and emerging Amyloid Centers of Excellence.
Pfizer: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain
Deadline: June 18th, 2021
The intent is to support virtual and potentially live programs and other innovative digital medical education for Health Care Professionals. The focus is on Osteoarthritis and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.
Pfizer: Centers for Therapeutic Innovation (CTI)
Deadline: June 28, 2021
Pfizer’s Centers for Therapeutic Innovation (CTI) Call for Proposals (CFP) to share details about our areas of interest and the timeline for submission of non-confidential pre-proposals this round. CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, and Internal Medicine.
- Quarter1 2018 (1)
- April 2019 (26)
- August 2019 (17)
- December 2019 (10)
- February 2019 (25)
- July 2019 (14)
- June 2019 (16)
- March 2019 (17)
- May 2019 (13)
- November 2019 (8)
- October 2019 (20)
- September 2019 (14)
- April 2020 (13)
- August 2020 (10)
- December 2020 (11)
- February 2020 (12)
- January 2020 (10)
- July 2020 (9)
- June 2020 (7)
- March 2020 (30)
- May 2020 (10)
- November 2020 (15)
- October 2020 (21)
- September 2020 (19)
- April 2021 (10)
- August 2021 (21)
- December 2021 (12)
- February 2021 (17)
- January 2021 (10)
- July 2021 (11)
- June 2021 (17)
- March 2021 (21)
- May 2021 (14)
- November 2021 (16)
- October 2021 (15)
- September 2021 (16)
- April 2022 (8)
- February 2022 (14)
- January 2022 (9)
- March 2022 (22)
- May 2022 (14)